Literature DB >> 35393626

Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood.

Katharina Strobel, Katja Maurus, Henning Hamm, Sabine Roth, Matthias Goebeler, Andreas Rosenwald, Marion Wobser1.   

Abstract

Pyogenic granuloma is one of the most common vascular tumours. The cause of pyogenic granuloma was previously thought to be an inflammatory reaction with consecutive stimulation of endothelial cell proliferation. However, recent studies suggest that pyogenic granuloma may be driven by constitutive activation of the mitogen-activated protein kinase pathway. The aim of this study was to investigate the molecular profile of sporadic pyogenic granuloma of childhood, using a systematic approach scrutinizing potential aberrations within different oncogenic pathways. Within a retrospective setting pyogenic granuloma of 15 patients was analysed by targeted next generation sequencing using the Oncomine Focus Assay, which includes genes of key tumorigenic signalling pathways. Activating mutations were found in 4 out of 15 cases (27%). Two HRAS hotspot mutations (p.Gly13Arg, p.Ala59Thr), 1 BRAF (p.Val600Glu) mutation and a novel, previously not reported, MAP2K1 hotspot mutation (p.Glu203Lys) were identified. It is notable that all of these genes are involved in constitutive mitogen- activated protein kinase signalling. This study increases the range of underlying genetic alterations in pyogenic granuloma by identifying novel oncogenic mutations in crucial mitogen-activated protein kinase pathway genes. The results provide supporting evidence that activated mitogen-activated protein kinase signalling is a key driver in the pathogenesis of pyogenic granuloma, which might be exploited by targeted treatment approaches for selected cases.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35393626      PMCID: PMC9558325          DOI: 10.2340/actadv.v102.1119

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  25 in total

1.  Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling.

Authors:  Huiyan Zeng; Dezheng Zhao; Suping Yang; Kaustubh Datta; Debabrata Mukhopadhyay
Journal:  J Biol Chem       Date:  2003-04-01       Impact factor: 5.157

2.  GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation.

Authors:  Young H Lim; Antonella Bacchiocchi; Jingyao Qiu; Robert Straub; Anna Bruckner; Lionel Bercovitch; Deepak Narayan; Jennifer McNiff; Christine Ko; Leslie Robinson-Bostom; Richard Antaya; Ruth Halaban; Keith A Choate
Journal:  Am J Hum Genet       Date:  2016-07-28       Impact factor: 11.025

3.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

Authors:  Sergey I Nikolaev; Donata Rimoldi; Christian Iseli; Armand Valsesia; Daniel Robyr; Corinne Gehrig; Keith Harshman; Michel Guipponi; Olesya Bukach; Vincent Zoete; Olivier Michielin; Katja Muehlethaler; Daniel Speiser; Jacques S Beckmann; Ioannis Xenarios; Thanos D Halazonetis; C Victor Jongeneel; Brian J Stevenson; Stylianos E Antonarakis
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

4.  Ras p21 proteins with high or low GTPase activity can efficiently transform NIH/3T3 cells.

Authors:  J C Lacal; S K Srivastava; P S Anderson; S A Aaronson
Journal:  Cell       Date:  1986-02-28       Impact factor: 41.582

5.  Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.

Authors:  Thaís Dos Santos Fontes Pereira; Larissa Stefhanne Damasceno de Amorim; Núbia Braga Pereira; Jéssica Gardone Vitório; Filipe Fideles Duarte-Andrade; Letícia Martins Guimarães; Marina Gonçalves Diniz; Carolina Cavaliéri Gomes; Ricardo Santiago Gomez
Journal:  J Oral Pathol Med       Date:  2019-08-04       Impact factor: 4.253

6.  Activated Ras induces a proangiogenic phenotype in primary endothelial cells.

Authors:  Kafi N Meadows; Patrick Bryant; Peter A Vincent; Kevin M Pumiglia
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

7.  Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Authors:  Yijun Gao; Matthew T Chang; Daniel McKay; Na Na; Bing Zhou; Rona Yaeger; Neilawattie M Torres; Keven Muniz; Matthias Drosten; Mariano Barbacid; Giordano Caponigro; Darrin Stuart; Henrik Moebitz; David B Solit; Omar Abdel-Wahab; Barry S Taylor; Zhan Yao; Neal Rosen
Journal:  Cancer Discov       Date:  2018-02-26       Impact factor: 39.397

8.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

Review 9.  Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer.

Authors:  Galia Maik-Rachline; Avital Hacohen-Lev-Ran; Rony Seger
Journal:  Int J Mol Sci       Date:  2019-03-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.